Drugs Made In America Acquisition II Corp. (DMII) financials — revenue, cash, debt and margins

Drugs Made In America Acquisition II Corp. (DMII) financials — revenue, cash, debt and margins — InspectStocks

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $647.2M
P/E (TTM): —
Price / sales: —
EV / EBITDA: —
Price / book: —

Cash flow

FCF yield: —
SBC-adjusted FCF yield: —
SBC impact: —
Stock compensation (TTM): —

Margins & growth

Profit margin: —
Operating margin: —
Quarterly revenue (year on year): —
Quarterly earnings (year on year): —

Balance sheet

Cash & investments: $175K
Debt: $450K
Net cash / (debt): -$275K

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

$13.02MQ2 2026+51.7%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

About Drugs Made In America Acquisition II Corp.

Ticker: DMII
SEC classification: Blank Checks (6770)
Listed on: Nasdaq
Financial year ends: December 31
Filer size: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

About this data

Everything above comes from Drugs Made In America Acquisition II Corp.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, R&D Expense, Interest Expense, Income Tax Expense, Profit per share, Shares outstanding, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Deposits, Loans, Short-term Investments, Inventory, Receivables, Long-term Debt (noncurrent), Long-term Debt (current), Borrowings (total), Operating Lease (current), Operating Lease (noncurrent), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Capital Expenditures, Dividends paid, Stock-Based Compensation, Depreciation & Amortization, Depreciation, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.